Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CURX
stocks logo

CURX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Curanex Pharmaceuticals Inc (CURX.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Curanex Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

CURX News & Events

Events Timeline

(ET)
2025-10-22
07:13:04
Curanex Partners with Strategic Investor Relations to Boost Visibility
select
2025-08-26 (ET)
2025-08-26
10:46:51
Curanex Debuts at $3.80 After IPO Set at $4 per Share
select
2025-08-26
07:36:01
Curanex Sets Initial Public Offering Price at $4.00 for 3.75 Million Shares
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
09-18Benzinga
"20 Stocks Making Moves in Premarket as Bullish Shares Rise by 12%"

  • Bullish Earnings Report: Bullish (BLSH) shares surged 12.3% in pre-market trading after reporting a profit of 93 cents per share for Q2, a significant improvement from a loss of $1.03 per share a year ago, with revenues rising to $58.63 million.

  • Notable Gainers: 89bio, Inc. (ETNB) saw an 82.9% increase due to an acquisition by Roche, while other stocks like Psyence Biomedical Ltd (PBM) and Aptevo Therapeutics Inc (APVO) also experienced significant gains in pre-market trading.

  • Major Losers: Wheeler Real Estate Investment Trust, Inc. (WHLR) dropped 23.1% following a reverse stock split announcement, and other companies like Office Properties Income Trust (OPI) and Educational Development Corporation (EDUC) also faced declines in pre-market trading.

  • Market Overview: The pre-market trading session showed a mix of sharp gains and losses among various stocks, reflecting a volatile market environment influenced by earnings reports and corporate announcements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Curanex Pharmaceuticals Inc (CURX) stock price today?

The current price of CURX is 0.4453 USD — it has increased 0.91 % in the last trading day.

arrow icon

What is Curanex Pharmaceuticals Inc (CURX)'s business?

Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).

arrow icon

What is the price predicton of CURX Stock?

Wall Street analysts forecast CURX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CURX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Curanex Pharmaceuticals Inc (CURX)'s revenue for the last quarter?

Curanex Pharmaceuticals Inc revenue for the last quarter amounts to -951.33K USD, decreased % YoY.

arrow icon

What is Curanex Pharmaceuticals Inc (CURX)'s earnings per share (EPS) for the last quarter?

Curanex Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Curanex Pharmaceuticals Inc (CURX)'s fundamentals?

The market is revising No Change the revenue expectations for CURX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -93.84%.
arrow icon

How many employees does Curanex Pharmaceuticals Inc (CURX). have?

Curanex Pharmaceuticals Inc (CURX) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Curanex Pharmaceuticals Inc (CURX) market cap?

Today CURX has the market capitalization of 12.62M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free